GlassScriptPhysician profile
Syed A Riaz
NPI 1104072727
$11,550.59
in general payments reported to CMS, 2019-2025
22 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 79% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $23.29 · 2021: $14.29 · 2022: $72.52 · 2023: $2,355 · 2024: $7,019 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,599 · Travel and Lodging: $2,917 · Food and Beverage: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,599.26 |
| Travel and Lodging | $2,917.19 |
| Food and Beverage | $1,960.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,634.13 | 2023-2025 | Da Vinci Surgical System |
| Noah Medical Corporation | $2,229.17 | 2023 | |
| Covidien LP | $885.26 | 2019 | |
| Glaxosmithkline, LLC. | $404.95 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pulmonx Corporation | $332.21 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Regeneron Healthcare Solutions, INC. | $312.42 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $188.16 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Harmony Biosciences LLC | $85.40 | 2024-2025 | |
| Insmed, INC. | $72.83 | 2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $56.87 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $52.85 | 2023-2024 | Xolair |
| Actelion Pharmaceuticals US, INC. | $47.46 | 2025 | Uptravi, Opsumit |
| Genzyme Corporation | $39.91 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.58 | 2024 | Ofev |
| Amgen INC. | $32.99 | 2024-2025 | Tezspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $28.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2025 | Aralast |
| Boston Scientific Corporation | $23.60 | 2022 | |
| Grifols USA, LLC | $19.83 | 2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $18.59 | 2025 | |
| Lilly USA, LLC | $14.02 | 2025 | Zepbound |
| Veran Medical Technologies, INC. | $9.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.